Wirth Matthias, Schneider Günter
II. Medizinische Klinik, Technische Universität München, München, 81675, Germany.
II. Medizinische Klinik, Technische Universität München, München, 81675, Germany.
Trends Cancer. 2016 Jan;2(1):1-3. doi: 10.1016/j.trecan.2015.12.002. Epub 2015 Dec 19.
One approach to improve cancer treatment is to stratify patients and to develop subgroup-specific therapies. We will discuss the potential of MYC as a stratification marker in pancreatic ductal adenocarcinoma. Furthermore, we will point to possibilities for how to annotate the MYC status and how to target MYC-associated vulnerabilities.
一种改善癌症治疗的方法是对患者进行分层并开发针对亚组的疗法。我们将讨论MYC作为胰腺导管腺癌分层标志物的潜力。此外，我们将指出标注MYC状态以及针对与MYC相关的易损性的方法。
